NASDAQ: VCYTVeracyte Inc Stock Ownership - Who owns Veracyte?
Insider buying vs selling
Have Veracyte Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Karin Eastham | Director | 2025-12-05 | 10,000 | $7.94 | $79.40kBuy |
| Karin Eastham | Director | 2025-12-05 | 800 | $46.59 | $37.27kSell |
| Karin Eastham | Director | 2025-12-05 | 12,808 | $45.84 | $587.08kSell |
| Karin Eastham | Director | 2025-12-05 | 6,392 | $44.52 | $284.57kSell |
| Karin Eastham | Director | 2025-12-05 | 10,000 | $7.60 | $76.00kBuy |
| John Leite | Chief Commercial Officer-CLIA | 2025-12-04 | 1,278 | $47.51 | $60.72kSell |
| Marc Stapley | Chief Executive Officer | 2025-12-04 | 3,220 | $47.35 | $152.46kSell |
| Marc Stapley | Chief Executive Officer | 2025-12-04 | 4,448 | $46.90 | $208.62kSell |
| Rebecca Chambers | Chief Financial Officer | 2025-12-04 | 8,537 | $46.61 | $397.94kSell |
| Rebecca Chambers | Chief Financial Officer | 2025-12-04 | 4,741 | $47.25 | $224.01kSell |
VCYT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when VCYT insiders and whales buy or sell their stock.
VCYT Shareholders
What type of owners hold Veracyte Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 16.51% | 13,052,114 | $568.16M | Institution |
| Vanguard Group Inc | 10.76% | 8,504,088 | $370.18M | Institution |
| Artisan Partners Limited Partnership | 9.32% | 7,370,467 | $320.84M | Institution |
| Fmr LLC | 8.60% | 6,795,697 | $295.82M | Institution |
| Ark Investment Management LLC | 5.65% | 4,465,775 | $194.40M | Institution |
| State Street Corp | 5.31% | 4,199,674 | $182.81M | Institution |
| Brian G. Atwood | 4.57% | 3,616,221 | $157.41M | Insider |
| Versant Ventures III LLC | 4.57% | 3,616,221 | $157.41M | Insider |
| Samuel D. Colella | 4.57% | 3,616,221 | $157.41M | Insider |
| Tpg Group Holdings Sbs Advisors Inc | 4.49% | 3,551,929 | $154.62M | Insider |
VCYT vs Biotech Stocks
Veracyte Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.